NMPA Approved Drugs List – February 2026 Update
Key claim: China’s NMPA granted priority review and conditional approval to Sosimerasib Sulfate Tablets (Jilemei) as a first-line treatment for intermediate-2 or high-risk primary myelofibrosis, post-PV myelofibrosis, and post-ET myelofibrosis.
Abstract
The NMPA granted priority review and conditional approval to Sosimerasib Sulfate Tablets (Jilemei) for first-line treatment of intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis.
Why this matters
Sosimerasib Sulfate Tablets (Jilemei) becomes one of the few agents to receive a regulatory label spanning primary PMF and both post-PV and post-ET myelofibrosis as a first-line indication for intermediate-2/high-risk disease — uniting the three fibrotic MPN subtypes under a shared frontline approval and extending the global MF treatment landscape into the NMPA jurisdiction. For subtype natural-history tracking, the approval reinforces post-PV MF and post-ET MF as clinically actionable transformation endpoints (not merely descriptive phases) and adds a new agent to the frontline higher-risk PMF armamentarium alongside ruxolitinib, fedratinib, pacritinib, and momelotinib.